A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy
Version of Record online: 15 APR 2014
© 2014 British HIV Association
Volume 15, Issue 7, pages 442–448, August 2014
How to Cite
Revell, A., Boyd, M., Wang, D., Emery, S., Gazzard, B., Reiss, P., van Sighem, A., Montaner, J., Lane, H. and Larder, B. (2014), A comparison of computational models with and without genotyping for prediction of response to second-line HIV therapy. HIV Medicine, 15: 442–448. doi: 10.1111/hiv.12156
- Issue online: 9 JUL 2014
- Version of Record online: 15 APR 2014
- Manuscript Accepted: 24 FEB 2014
- National Cancer Institute
- National Institutes of Health. Grant Number: HHSN261200800001E
- National Institute of Allergy and Infectious Diseases
- 3World Health Organisation. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for A Public Health Approach. Geneva, WHO, 2013.
- 4Second-Line Study Group. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381: 2091–2099.
- 9The development of new computational models for the HIV-TRePS online treatment selection tool. XIX International AIDS Conference. Washington DC, USA, July 2012 [Abstract TUPE091]., , et al.